Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer(University Hospital of Zurich), Keith T. Flaherty(Cancer Research Center), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Laure A Moutouh-de Parseval(Novartis (Switzerland)), Jan Willem B. de Groot(Isala), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Michael D. Pickard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Carmen Loquai(Johannes Gutenberg University Mainz), Helen Gogas(National and Kapodistrian University of Athens), Caroline Robert(Institut Gustave Roussy), Claus Garbe(University of Tübingen), Victor Sandor(Peter MacCallum Cancer Centre), Naoya Yamazaki(Tokyo National Hospital)
Cited by 586
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k